Selling a Cardiology Practice in 2026: Multiples, Named Buyers, and the MSO Playbook
Quick Answer
A US cardiology practice in 2026 typically sells for roughly 6x to 12x EBITDA. Cardiology M&A is a relatively new consolidation cycle (started in earnest 2022-2023) driven by ancillary economics (in-office echo, nuclear, stress testing, vascular ultrasound) and the cardiologists’ migration from hospital employment back to independent practice via PE-MSO. By profile: single-MD cardiology ($500k-1.5M EBITDA) goes 5x-7x; multi-MD single-site or 2-3 location practice ($1.5-5M EBITDA) goes 6x-9x; small regional cardiology group with ancillary integration ($3-10M EBITDA) goes 7x-10x; mid-size platform ($10-30M EBITDA, multi-site, full diagnostic suite + interventional + EP) goes 9x-11x; premium scale platform ($30M+ EBITDA, multi-state, named commercial in-network, value-based-care positioning) reaches 10x-12x+. Active buyers include US Heart & Vascular (Ares Management, the dominant US cardiology MSO with ~600+ providers), Cardiovascular Associates of America / CVA (Webster Equity Partners, multi-state platform), US Cardiology Partners (PE-backed), Cardio Partners (PE-backed), Florida Heart Group, Cardio One (PE), plus PE sponsors (Ares Management, Webster Equity Partners, NMS Capital, Audax Group, Charlesbank Capital Partners). The biggest multiple drivers are ancillary services integration (in-office echo, nuclear cardiology, stress testing, vascular ultrasound; cath lab if applicable), subspecialty mix (interventional + electrophysiology premium), commercial payer mix, value-based-care positioning (CMS BPCI Advanced for cardiac care), and modern cardiology EMR (Modernizing Medicine EMA-Cardio, Epic, eClinicalWorks-Cardio). Buyer-paid M&A advisory (CT Strategic Partners) costs the seller nothing.
If you own a US cardiology practice in 2026, the M&A market is in a newer but rapidly-accelerating consolidation cycle. US Heart & Vascular (Ares Management) leads at ~600+ providers. Cardiovascular Associates of America / CVA (Webster Equity Partners), US Cardiology Partners, Cardio Partners, and several regional PE-backed platforms compete. Cardiologists are migrating from hospital employment back to PE-MSO-owned independent practice driven by ancillary economics and value-based-care opportunity.
What the asset is worth depends on three things: (1) ancillary services integration (in-office echo, nuclear cardiology, stress testing, vascular ultrasound, cath lab if applicable), (2) subspecialty mix (interventional cardiology and electrophysiology premium), and (3) commercial payer mix plus value-based-care positioning. This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.
What this guide covers
- Cardiology multiples 2026: 5x-7x for single-MD, 6x-9x for multi-MD, 7x-10x for small regional with ancillary integration, 9x-11x for mid-size platforms, 10x-12x+ for premium scale.
- Active buyers: US Heart & Vascular (Ares Management, ~600+ providers, dominant US cardiology MSO), Cardiovascular Associates of America / CVA (Webster Equity Partners), US Cardiology Partners (PE), Cardio Partners (PE), Florida Heart Group, Cardio One (PE).
- PE sponsor activity: Ares Management (US Heart & Vascular), Webster Equity Partners (CVA), NMS Capital, Audax Group, Charlesbank Capital Partners.
- Multiple drivers: ancillary services integration (in-office echo, nuclear, stress testing, vascular ultrasound; cath lab if applicable), subspecialty mix (interventional + EP premium), commercial payer mix, value-based-care (CMS BPCI Advanced for cardiac care, Medicare Advantage primary-care cardiology contracts), modern cardiology EMR.
- Things that compress: weak ancillary integration, owner-MD dependence, Medicare-heavy payer mix, weak commercial in-network status, single-state, no value-based-care positioning.
- Sellers pay nothing on CT Strategic Partners’ buyer-paid advisory.
Named M&A transactions (2021-2025)
| Target | Buyer | Year | What it tells us |
|---|---|---|---|
| US Heart & Vascular continued growth | Ares Management | 2022-2025 | Dominant US cardiology MSO continues aggressive tuck-in M&A. |
| CVA expansion | Webster Equity Partners | 2022-2025 | Multi-state cardiology platform continues regional rollups. |
| US Cardiology Partners growth | PE-backed | 2022-2025 | Regional cardiology platform continues consolidation. |
| Multiple regional cardiology tuck-ins | Various PE platforms | 2022-2025 | PE sponsors continue cardiology consolidation. |
| Cardiologists return from hospital employment | Various PE-MSO platforms | 2022-2025 | Major industry trend: physicians migrating from hospital employment back to PE-MSO independent practice. |
The named buyer landscape
PE-backed national cardiology MSOs
- US Heart & Vascular (Ares Management) — ~600+ providers, the dominant US cardiology MSO.
- Cardiovascular Associates of America / CVA (Webster Equity Partners) — multi-state.
- US Cardiology Partners (PE-backed).
- Cardio Partners (PE-backed).
- Cardio One (PE-backed).
- Florida Heart Group.
PE sponsors active in this space
- Ares Management (US Heart & Vascular), Webster Equity Partners (CVA), NMS Capital, Audax Group, Charlesbank Capital Partners.
Hospital systems re-emerging as buyers
- Hospital systems acquire cardiology practices for cardiac service-line strategy. The 2022-2025 PE-MSO wave attracted physicians from hospital employment; some hospital systems re-enter as acquirers for strategic alignment.
What each buyer will pay for vs. what they reject
- Will pay premium for: ancillary services integration (in-office echo, nuclear cardiology, stress testing, vascular ultrasound, peripheral vascular), subspecialty mix (interventional cardiology, electrophysiology / EP, heart failure, structural heart), cath lab ownership where structured, commercial payer mix 55%+, value-based-care contract participation (CMS BPCI Advanced for cardiac, Medicare Advantage primary-care cardiology), modern EMR.
- Will compress or reject: weak ancillary integration, owner-MD dependence, Medicare-heavy payer mix above 60%, weak commercial in-network, single-state, no value-based-care positioning, weak diagnostic equipment investment.
The operator-level KPI playbook buyers will diligence
Subspecialty mix
- General cardiology, invasive non-interventional, interventional cardiology, electrophysiology / EP, heart failure, structural heart, vascular medicine.
- Cath lab and EP lab volume if applicable.
Ancillary services
- In-office echocardiography volume.
- Nuclear cardiology (SPECT, PET) volume.
- Stress testing volume.
- Vascular ultrasound (carotid, peripheral, abdominal) volume.
- CT angiography / coronary CTA if equipped.
- Holter / event monitor volume.
Payer mix
- Commercial percentage: 55%+ benchmark.
- Medicare percentage: 35-50% typical (aging-demographic skew).
- Medicare Advantage primary-care cardiology contracts.
- BPCI Advanced cardiac bundles.
Provider bench
- MD count and subspecialty.
- APP scaling.
- Provider productivity.
- Equity-rollover expectations (PE-MSO cardiology deals typically 30-50%).
Dangers and traps
1. Weak ancillary integration
Echo, nuclear, stress testing, vascular ultrasound are the major multiple-builders.
2. Owner-MD dependence
Build MD/APP bench.
3. Medicare-heavy payer mix
Above 60% Medicare compresses.
4. Single-state operations
Multi-state path matters.
5. Stark and anti-kickback exposure
In-office ancillary services exception requires Stark-compliant structure.
6. Weak value-based-care positioning
BPCI Advanced and MA cardiology contracts are growing.
7. Aging diagnostic equipment
Echo machines and nuclear cameras have replacement cycles.
8. Equity rollover expectations
PE-MSO cardiology deals typically 30-50% rollover.
Our POV in 2026
Cardiology M&A is in a relatively new but accelerating consolidation cycle. US Heart & Vascular (Ares Management) leads at ~600+ providers. CVA, US Cardiology Partners, Cardio Partners, and regional PE-backed platforms compete. Cardiologists are returning from hospital employment to PE-MSO independent practice via ancillary economics and value-based-care opportunity.
The right time to prepare is 12-18 months before going to market — integrate diagnostic ancillaries, build subspecialty bench, develop value-based-care positioning.
Preparing your business for sale: 12-18 months out
- Get multi-year audited financials.
- Integrate ancillaries (echo, nuclear, stress testing, vascular ultrasound, CTA).
- Develop subspecialty bench (interventional, EP, heart failure, structural heart).
- Confirm Stark-compliant ancillary structure.
- Develop value-based-care positioning.
- Confirm commercial in-network status.
- Build the MD/APP bench.
- Modernize EMR.
- Run a competitive process. US Heart & Vascular (Ares Management), Cardiovascular Associates of America (Webster Equity Partners), US Cardiology Partners, Cardio Partners, Cardio One, Florida Heart Group, plus PE sponsors directly (Ares Management, Webster Equity Partners, NMS Capital, Audax Group, Charlesbank Capital Partners).
About the Author
Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch
Free, No Email Required
Get a personalized valuation in 90 seconds
Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.
Open the Valuation Tool →The five pillars of how CT Acquisitions works
Buyer pays our fee. Founders never write a check.
No engagement letter. No upfront cost. No exclusivity contract.
Search funders, family offices, lower-middle-market PE, strategics.
Confidential introductions to the right buyers. No bidding war.
Not 9-12 months. Not 18 months. Months, not years.
No Pitch · No Pressure
Ready to start a confidential conversation?
Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next 60-120 days could look like. No engagement letter. No retainer. Walk at any time.
Start a Confidential Conversation →Frequently asked questions
What is the typical multiple for a cardiology practice in 2026?
Single-MD cardiology practices ($500k-1.5M EBITDA) typically sell at 5x-7x EBITDA. Multi-MD single-site or 2-3 location practices ($1.5-5M EBITDA) go 6x-9x. Small regional cardiology groups with ancillary integration ($3-10M EBITDA) go 7x-10x. Mid-size platforms ($10-30M EBITDA, multi-site, full diagnostic suite + interventional + EP) go 9x-11x. Premium scale platforms ($30M+ EBITDA, multi-state, named commercial in-network, value-based-care positioning) reach 10x-12x+.
Who are the active buyers of cardiology practices right now?
PE-backed national cardiology MSOs: US Heart & Vascular (Ares Management, ~600+ providers, dominant US cardiology MSO), Cardiovascular Associates of America / CVA (Webster Equity Partners), US Cardiology Partners, Cardio Partners, Cardio One, Florida Heart Group. PE sponsors: Ares Management, Webster Equity Partners, NMS Capital, Audax Group, Charlesbank Capital Partners.
What hurts a cardiology practice’s valuation most?
Weak ancillary integration (echo, nuclear, stress testing, vascular ultrasound are the major multiple-builders), owner-MD dependence, Medicare-heavy payer mix above 60%, weak commercial in-network status, single-state operations, Stark or anti-kickback exposure on in-office ancillaries, weak value-based-care positioning, and aging diagnostic equipment.
Why is cardiology M&A a newer consolidation cycle?
Cardiology M&A accelerated meaningfully in 2022-2023 as cardiologists began migrating from hospital employment back to independent practice via PE-MSO structures. The migration was driven by ancillary economics (in-office echo + nuclear + vascular ultrasound) that hospital employment compressed, and value-based-care opportunity (BPCI Advanced cardiac, Medicare Advantage cardiology). US Heart & Vascular (Ares Management) emerged as the dominant platform; the consolidation cycle continues.
Do I have to pay a broker fee?
No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing.
How long does it take to sell a cardiology practice?
Typical process 5-9 months. Add 12-18 months of preparation.
What is the typical equity rollover in a cardiology MSO transaction?
PE-MSO cardiology deals typically include 30-50% equity rollover for selling MDs. The rollover equity participates in the next platform exit.
When should I start preparing if I plan to sell in 2027 or 2028?
12-18 months before going to market. Highest-leverage work: integrate diagnostic ancillaries, build subspecialty bench, develop value-based-care positioning.
Related research
- How to sell a gastroenterology practice
- How to sell an orthopedic practice
- How to sell an ophthalmology practice
- How to sell a pain management practice
- How to sell an imaging center
- How to sell an urgent care center
- How to sell a clinical laboratory
- Healthcare business valuation
- Which industries is PE buying most in 2026
- Business broker alternative